Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-552-500"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-10-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"lt"^^xsd:language2
lpv:document identification number	"en.20121023.45.2-552-500"2
lpv:hasSubsequent	lp_eu:2012-10-23-Speech-2-553-0002
lpv:speaker	lp:Laima Liucija Andrikienė2
lpv:spokenAs	member; DROI (2012-01-19--2014-06-30)3 substitute; Delegation to the EU-Mexico Joint Parliamentary Committee (2009-10-12--2014-06-30)3 member; EPP (2009-07-14--2014-06-30)3 member; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2014-06-30)3 member; Delegation for relations with Belarus (2009-09-16--2014-06-30)3 member; INTA (2012-01-19--2014-06-30)3 substitute; AFET (2012-01-19--2014-06-30)3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-10-12--2014-06-30)3 unknown; Tėvynės sąjunga - Lietuvos krikščionys demokratai (2009-07-14--2014-06-30)3
lpv:translated text	"I welcome the result of the European Parliament’s vote giving consent to the Protocol to the EU-Israel Agreement on conformity assessment and acceptance of industrial products (ACAA): 379 in favour, 230 against with 41 abstentions. Also I would like to express my gratitude to those colleagues who supported this important resolution. The vote endorsed the PPE Group line on this important agreement between the EU and Israel, whose Additional Protocol on pharmaceutical products will help to facilitate market access by eliminating technical barriers to trade on industrial products. Once in force, the ACAA foresees mutual recognition of regulatory and verification procedures for pharmaceutical products in the EU and Israel. Such mutual recognition would certainly benefit European consumers. Since there would no longer be a need for additional testing in the EU, something that normally takes from one to three years, European consumers would get quicker access to Israeli pharmaceutical products. It means that EU citizens will benefit directly from this Agreement as they will be able to get good quality pharmaceutical products from Israel quicker and cheaper."@en1
lpv:unclassifiedMetadata	"Laima Liucija Andrikienė (PPE ),"1 "in writing."1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph